{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T19:23:15Z","timestamp":1771528995304,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"natural science foundation","award":["82170514"],"award-info":[{"award-number":["82170514"]}]},{"DOI":"10.13039\/100018975","name":"Jiangsu Office of Philosophy and Social Science","doi-asserted-by":"publisher","award":["YJXYY202204"],"award-info":[{"award-number":["YJXYY202204"]}],"id":[{"id":"10.13039\/100018975","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Digit Imaging. Inform. med."],"DOI":"10.1007\/s10278-024-01381-7","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T17:37:08Z","timestamp":1747071428000},"page":"299-310","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prediction of PD-1 Expression and Outcomes of Combined Therapy in Hepatocellular Carcinoma: an MRI-Based Radiomics Approach"],"prefix":"10.1007","volume":"39","author":[{"given":"Jingxiao","family":"Gu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanlei","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongzheng","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"1381_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, et al (2021) Hepatocellular carcinoma. Nat Rev Dis Primers 7:6. https:\/\/doi.org\/10.1038\/s41572-020-00240-3","journal-title":"Nat Rev Dis Primers"},{"key":"1381_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","volume":"23","author":"T Yau","year":"2022","unstructured":"Yau T, Park J-W, Finn RS, et al (2022) Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. The Lancet Oncology 23:77\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(21)00604-5","journal-title":"The Lancet Oncology"},{"key":"1381_CR3","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. The Lancet 389:2492\u20132502. https:\/\/doi.org\/10.1016\/S0140-6736(17)31046-2","journal-title":"The Lancet"},{"key":"1381_CR4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I (2017) Elements of cancer immunity and the cancer\u2013immune set point. Nature 541:321\u2013330. https:\/\/doi.org\/10.1038\/nature21349","journal-title":"Nature"},{"key":"1381_CR5","doi-asserted-by":"publisher","unstructured":"Gnjatic S, Bronte V, Brunet LR, et al (2017) Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. j immunotherapy cancer 5:44. https:\/\/doi.org\/10.1186\/s40425-017-0243-4","DOI":"10.1186\/s40425-017-0243-4"},{"key":"1381_CR6","unstructured":"Immune escape to PD L1.PDF"},{"key":"1381_CR7","doi-asserted-by":"publisher","first-page":"1070961","DOI":"10.3389\/fimmu.2022.1070961","volume":"13","author":"Q Li","year":"2022","unstructured":"Li Q, Han J, Yang Y, Chen Y (2022) PD-1\/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Front Immunol 13:1070961. https:\/\/doi.org\/10.3389\/fimmu.2022.1070961","journal-title":"Front Immunol"},{"key":"1381_CR8","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1038\/ncomms5006","volume":"5","author":"HJWL Aerts","year":"2014","unstructured":"Aerts HJWL, Velazquez ER, Leijenaar RTH, et al (2014) Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 5:4006. https:\/\/doi.org\/10.1038\/ncomms5006","journal-title":"Nat Commun"},{"key":"1381_CR9","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1038\/s41598-017-02706-z","volume":"7","author":"SJ Hectors","year":"2017","unstructured":"Hectors SJ, Wagner M, Bane O, et al (2017) Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging. Sci Rep 7:2452. https:\/\/doi.org\/10.1038\/s41598-017-02706-z","journal-title":"Sci Rep"},{"key":"1381_CR10","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1002\/nbm.2962","volume":"26","author":"J Fruehwald-Pallamar","year":"2013","unstructured":"Fruehwald-Pallamar J, Czerny C, Holzer-Fruehwald L, et al (2013) Texture-based and diffusion-weighted discrimination of parotid gland lesions on MR images at 3.0 Tesla: TEXTURE ANALYSIS AND DWI OF PAROTID GLAND LESIONS. NMR Biomed 26:1372\u20131379. https:\/\/doi.org\/10.1002\/nbm.2962","journal-title":"NMR Biomed"},{"key":"1381_CR11","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.media.2013.10.005","volume":"18","author":"A Depeursinge","year":"2014","unstructured":"Depeursinge A, Foncubierta-Rodriguez A, Van De Ville D, M\u00fcller H (2014) Three-dimensional solid texture analysis in biomedical imaging: Review and opportunities. Medical Image Analysis 18:176\u2013196. https:\/\/doi.org\/10.1016\/j.media.2013.10.005","journal-title":"Medical Image Analysis"},{"key":"1381_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.mbs.2018.06.004","volume":"303","author":"R Alhamzawi","year":"2018","unstructured":"Alhamzawi R, Ali HTM (2018) The Bayesian adaptive lasso regression. Mathematical Biosciences 303:75\u201382. https:\/\/doi.org\/10.1016\/j.mbs.2018.06.004","journal-title":"Mathematical Biosciences"},{"key":"1381_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059771","volume":"8","author":"L-Q Kong","year":"2013","unstructured":"Kong L-Q, Zhu X-D, Xu H-X, et al (2013) The Clinical Significance of the CD163+ and CD68+ Macrophages in Patients with Hepatocellular Carcinoma. PLoS ONE 8:e59771. https:\/\/doi.org\/10.1371\/journal.pone.0059771","journal-title":"PLoS ONE"},{"key":"1381_CR14","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s12072-019-09967-y","volume":"13","author":"L Wang","year":"2019","unstructured":"Wang L, Wang F-S (2019) Clinical immunology and immunotherapy for hepatocellular carcinoma: current progress and challenges. Hepatol Int 13:521\u2013533. https:\/\/doi.org\/10.1007\/s12072-019-09967-y","journal-title":"Hepatol Int"},{"key":"1381_CR15","doi-asserted-by":"publisher","first-page":"1019772","DOI":"10.3389\/fimmu.2022.1019772","volume":"13","author":"W Qiao","year":"2022","unstructured":"Qiao W, Wang Q, Hu C, et al (2022) Interim efficacy and safety of PD-1 inhibitors in preventing recurrence of hepatocellular carcinoma after interventional therapy. Front Immunol 13:1019772. https:\/\/doi.org\/10.3389\/fimmu.2022.1019772","journal-title":"Front Immunol"},{"key":"1381_CR16","doi-asserted-by":"publisher","first-page":"5351","DOI":"10.1038\/s41598-018-21937-2","volume":"8","author":"F Foerster","year":"2018","unstructured":"Foerster F, Hess M, Gerhold-Ay A, et al (2018) The immune contexture of hepatocellular carcinoma predicts clinical outcome. Sci Rep 8:5351. https:\/\/doi.org\/10.1038\/s41598-018-21937-2","journal-title":"Sci Rep"},{"key":"1381_CR17","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1007\/s00330-020-06675-2","volume":"30","author":"SJ Hectors","year":"2020","unstructured":"Hectors SJ, Lewis S, Besa C, et al (2020) MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma. Eur Radiol 30:3759\u20133769. https:\/\/doi.org\/10.1007\/s00330-020-06675-2","journal-title":"Eur Radiol"},{"key":"1381_CR18","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1158\/1078-0432.CCR-18-3190","volume":"25","author":"Z Liu","year":"2019","unstructured":"Liu Z, Li Z, Qu J, et al (2019) Radiomics of Multiparametric MRI for Pretreatment Prediction of Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer: A Multicenter Study. Clinical Cancer Research 25:3538\u20133547. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3190","journal-title":"Clinical Cancer Research"},{"key":"1381_CR19","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/jmri.27143","volume":"52","author":"Y Sun","year":"2020","unstructured":"Sun Y, Bai H, Xia W, et al (2020) Predicting the Outcome of Transcatheter Arterial Embolization Therapy for Unresectable Hepatocellular Carcinoma Based on Radiomics of Preoperative Multiparameter MRI. Magnetic Resonance Imaging 52:1083\u20131090. https:\/\/doi.org\/10.1002\/jmri.27143","journal-title":"Magnetic Resonance Imaging"},{"key":"1381_CR20","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41571-021-00560-7","volume":"19","author":"K Bera","year":"2022","unstructured":"Bera K, Braman N, Gupta A, et al (2022) Predicting cancer outcomes with radiomics and artificial intelligence in radiology. Nat Rev Clin Oncol 19:132\u2013146. https:\/\/doi.org\/10.1038\/s41571-021-00560-7","journal-title":"Nat Rev Clin Oncol"},{"key":"1381_CR21","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.acra.2007.10.022","volume":"15","author":"BJ Youn","year":"2008","unstructured":"Youn BJ, Chung JW, Son KR, et al (2008) Diffusion-Weighted MR: Therapeutic Evaluation After Chemoembolization of VX-2 Carcinoma Implanted in Rabbit Liver. Academic Radiology 15:593\u2013600. https:\/\/doi.org\/10.1016\/j.acra.2007.10.022","journal-title":"Academic Radiology"},{"key":"1381_CR22","doi-asserted-by":"publisher","unstructured":"Yuan Z (2015) Diffusion-Weighted MR Imaging of Hepatocellular Carcinoma_ Current Value in Clinical Evaluation of Tumor Response to Locoregional Treatment. J Vasc Interv Radiol. 2016 Jan;27(1):20\u201330; quiz 31. https:\/\/doi.org\/10.1016\/j.jvir.2015.10.003.","DOI":"10.1016\/j.jvir.2015.10.003"},{"key":"1381_CR23","doi-asserted-by":"publisher","unstructured":"Chamming\u2019s F, Ueno Y, Ferr\u00e9 R, et al (2018) Features from Computerized Texture Analysis of Breast Cancers at Pretreatment MR Imaging Are Associated with Response to Neoadjuvant Chemotherapy. Radiology 286:412\u2013420. https:\/\/doi.org\/10.1148\/radiol.2017170143","DOI":"10.1148\/radiol.2017170143"},{"key":"1381_CR24","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1148\/radiol.2018181717","volume":"289","author":"NM deSouza","year":"2018","unstructured":"deSouza NM (2018) Diffusion-weighted MRI in Multicenter Trials of Breast Cancer: A Useful Measure of Tumor Response? Radiology 289:628\u2013629. https:\/\/doi.org\/10.1148\/radiol.2018181717","journal-title":"Radiology"},{"key":"1381_CR25","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.1007\/s00330-022-09302-4","volume":"33","author":"R Zhang","year":"2022","unstructured":"Zhang R, Zhang Q, Ji A, et al (2022) Prediction of new cerebral ischemic lesion after carotid artery stenting: a high-resolution vessel wall MRI-based radiomics analysis. Eur Radiol 33:4115\u20134126. https:\/\/doi.org\/10.1007\/s00330-022-09302-4","journal-title":"Eur Radiol"},{"key":"1381_CR26","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/sj.bjc.6601018","volume":"88","author":"R Cui","year":"2003","unstructured":"Cui R, He J, Zhang F, et al (2003) Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to \u03b1-fetoprotein. Br J Cancer 88:1878\u20131882. https:\/\/doi.org\/10.1038\/sj.bjc.6601018","journal-title":"Br J Cancer"},{"key":"1381_CR27","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005811","volume":"96","author":"SJ Park","year":"2017","unstructured":"Park SJ, Jang JY, Jeong SW, et al (2017) Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma. Medicine 96:e5811. https:\/\/doi.org\/10.1097\/MD.0000000000005811","journal-title":"Medicine"},{"key":"1381_CR28","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3109\/00365521.2015.1082190","volume":"51","author":"TS Lim","year":"2016","unstructured":"Lim TS, Kim DY, Han K-H, et al (2016) Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. Scandinavian Journal of Gastroenterology 51:344\u2013353. https:\/\/doi.org\/10.3109\/00365521.2015.1082190","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"1381_CR29","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1186\/s12885-021-08428-w","volume":"21","author":"X Sun","year":"2021","unstructured":"Sun X, Mei J, Lin W, et al (2021) Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients. BMC Cancer 21:775. https:\/\/doi.org\/10.1186\/s12885-021-08428-w","journal-title":"BMC Cancer"},{"key":"1381_CR30","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.3390\/ijms18071517","volume":"18","author":"H Cho","year":"2017","unstructured":"Cho H, Kang H, Lee H, Kim C (2017) Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis. IJMS 18:1517. https:\/\/doi.org\/10.3390\/ijms18071517","journal-title":"IJMS"},{"key":"1381_CR31","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1097\/JS9.0000000000000256","volume":"109","author":"Y Yuan","year":"2023","unstructured":"Yuan Y, He W, Yang Z, et al (2023) TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study. International Journal of Surgery 109:1222\u20131230. https:\/\/doi.org\/10.1097\/JS9.0000000000000256","journal-title":"International Journal of Surgery"},{"key":"1381_CR32","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00535-023-01976-x","volume":"58","author":"Y Fu","year":"2023","unstructured":"Fu Y, Peng W, Zhang W, et al (2023) Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis. J Gastroenterol 58:413\u2013424. https:\/\/doi.org\/10.1007\/s00535-023-01976-x","journal-title":"J Gastroenterol"},{"key":"1381_CR33","unstructured":"Wang X-H MRI-based radiomics model for preoperative prediction of 5-year survival in patients with hepatocellular carcinoma"},{"key":"1381_CR34","doi-asserted-by":"publisher","unstructured":"Aguilar-Mahecha A, Hassan S, Ferrario C, Basik M (2006) Microarrays as Validation Strategies in Clinical Samples: Tissue and Protein Microarrays. OMICS: A Journal of Integrative Biology 10:311\u2013326. https:\/\/doi.org\/10.1089\/omi.2006.10.311","DOI":"10.1089\/omi.2006.10.311"}],"container-title":["Journal of Imaging Informatics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10278-024-01381-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10278-024-01381-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10278-024-01381-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T18:46:20Z","timestamp":1771526780000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10278-024-01381-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["1381"],"URL":"https:\/\/doi.org\/10.1007\/s10278-024-01381-7","relation":{},"ISSN":["2948-2933"],"issn-type":[{"value":"2948-2933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"assertion":[{"value":"25 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}